NO964155L - Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger - Google Patents

Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger

Info

Publication number
NO964155L
NO964155L NO964155A NO964155A NO964155L NO 964155 L NO964155 L NO 964155L NO 964155 A NO964155 A NO 964155A NO 964155 A NO964155 A NO 964155A NO 964155 L NO964155 L NO 964155L
Authority
NO
Norway
Prior art keywords
drugs
manufacture
uterine bleeding
dysfunctional uterine
progesterone antagonists
Prior art date
Application number
NO964155A
Other languages
English (en)
Norwegian (no)
Other versions
NO964155D0 (no
Inventor
Kristof Chwalsz
Klaus Stockemann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO964155L publication Critical patent/NO964155L/no
Publication of NO964155D0 publication Critical patent/NO964155D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO964155A 1995-02-02 1996-10-01 Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger NO964155D0 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1995/000394 WO1996023503A1 (de) 1995-02-02 1995-02-02 Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen

Publications (2)

Publication Number Publication Date
NO964155L true NO964155L (no) 1996-10-01
NO964155D0 NO964155D0 (no) 1996-10-01

Family

ID=8165951

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964155A NO964155D0 (no) 1995-02-02 1996-10-01 Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger

Country Status (20)

Country Link
US (1) US6451780B1 (ja)
EP (1) EP0806952B1 (ja)
JP (1) JPH10512889A (ja)
KR (1) KR100370908B1 (ja)
AT (1) ATE235907T1 (ja)
AU (1) AU714959B2 (ja)
CA (1) CA2186953C (ja)
DE (1) DE59510626D1 (ja)
DK (1) DK0806952T3 (ja)
ES (1) ES2196063T3 (ja)
FI (1) FI117850B (ja)
HU (1) HU226276B1 (ja)
MX (1) MX9603889A (ja)
NO (1) NO964155D0 (ja)
NZ (1) NZ287024A (ja)
PL (1) PL316533A1 (ja)
PT (1) PT806952E (ja)
SK (1) SK282570B6 (ja)
UA (1) UA37259C2 (ja)
WO (1) WO1996023503A1 (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375160T1 (de) 1999-08-31 2007-10-15 Bayer Schering Pharma Ag Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen
US8193252B1 (en) * 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
US20020176893A1 (en) * 2001-02-02 2002-11-28 Wironen John F. Compositions, implants, methods, and kits for closure of lumen openings, repair of ruptured tissue, and for bulking of tissue
US6685626B2 (en) 2001-02-02 2004-02-03 Regeneration Technologies, Inc. Compositions, devices, methods, and kits for induction of adhesions
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
CA2569738A1 (en) * 2004-06-07 2005-12-22 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
DK2148681T3 (en) * 2007-04-20 2016-07-04 Preglem Sa Selective progesteronmodulatorer in the treatment of uterine bleeding
US20090118253A1 (en) * 2007-11-05 2009-05-07 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
EP2854763B1 (en) 2012-05-31 2018-09-26 Repros Therapeutics Inc. Formulations for vaginal delivery of antiprogestins
WO2014070517A1 (en) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
CA3009522A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
AU2016379417B2 (en) 2015-12-23 2020-09-24 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
MX2019004030A (es) 2016-10-07 2019-09-16 Oric Pharmaceuticals Inc Inhibidores del receptor de glucocorticoides.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1918092A (en) * 1992-05-06 1993-11-29 Medical College Of Hampton Roads, The Minimizing progestin associated breakthrough bleeding
US5622943A (en) 1992-05-06 1997-04-22 The Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding

Also Published As

Publication number Publication date
EP0806952B1 (de) 2003-04-02
WO1996023503A1 (de) 1996-08-08
KR970704451A (ko) 1997-09-06
JPH10512889A (ja) 1998-12-08
UA37259C2 (uk) 2001-05-15
HU9602668D0 (en) 1996-11-28
FI117850B (fi) 2007-03-30
KR100370908B1 (ko) 2003-04-10
PL316533A1 (en) 1997-01-20
FI963049A0 (fi) 1996-08-01
DE59510626D1 (de) 2003-05-08
DK0806952T3 (da) 2003-06-16
AU714959B2 (en) 2000-01-13
NO964155D0 (no) 1996-10-01
FI963049A (fi) 1996-10-01
ES2196063T3 (es) 2003-12-16
EP0806952A1 (de) 1997-11-19
MX9603889A (es) 1997-04-30
ATE235907T1 (de) 2003-04-15
US6451780B1 (en) 2002-09-17
SK282570B6 (sk) 2002-10-08
NZ287024A (en) 2001-03-30
CA2186953C (en) 2009-11-10
HUT75930A (en) 1997-05-28
AU2561195A (en) 1996-08-21
SK121996A3 (en) 1997-05-07
CA2186953A1 (en) 1996-08-08
PT806952E (pt) 2003-08-29
HU226276B1 (en) 2008-07-28

Similar Documents

Publication Publication Date Title
NO964155D0 (no) Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
DE60107687D1 (de) Cyclpentanoindole, mischungen derartige verbindungen enthaltend und behandlungsmethoden
SE0100568D0 (sv) Compounds
ATE390917T1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
DZ3265A1 (fr) Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2
NO994850L (no) Farmakologiske midler
NO164656C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktivt 1-(4-amionfenyl)-4-methyl-7,8-methylendioxy-3,4-dihydro-5h-2,3-benzodiazepin.
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
EA199800692A1 (ru) Изолируемые смеси из семян eugenia jambolana lamarck, способы их получения, способ получения оксамата натрия, лекарственные средства для профилактики и лечения диабета и применение указанных смесей, их компонентов и оксамата натрия для получения этих лекарственных средств
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
ATE286883T1 (de) Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität
NO971869D0 (no) Konkurransedyktige progesteronantagonister for behovsorientert, kvinnelig fertillitetskontroll
TR200100637T2 (tr) Yeni doğal ürün türevleri
FI973023A0 (fi) Liikakasvusairauksien yhdistetty terapeuttinen hoito
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
ES2188908T3 (es) Derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes relacionados con el estrogenos.
SE0101692D0 (sv) Compounds
DE3380923D1 (de) Pharmazeutische zusammensetzungen zur behandlung von stoerungen, bedingt durch humanendrogen.
ES2188909T3 (es) Nuevos derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes o enfermedades relacionados con el estrogeno. os
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
TR200000916T2 (tr) İkameli piperidin türevleri.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application